Finotonlimab clinical trials
Also written SCT-I10A.
How each study uses finotonlimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the finotonlimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 5
Sinocelltech Ltd. (3) · Sun Yat-sen University (1) · Tang-Du Hospital (1) · Yanjie Zhang, MD (1) · Eye & ENT Hospital of Fudan University (1) · Beijing Tongren Hospital (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test finotonlimab.
- Jun 2027Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCCPhase 1 · Beijing Tongren Hospital
Studies
Open first, then newest update. How each study uses finotonlimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Neoadjuvant Finotonlimab Plus TP Regimen in Locally Advanced INI-1-Deficient Sinonasal CarcinomaRecruitingPhase 2Eye & ENT Hospital of Fudan UniversityNCT07927465Written as Finotonlimab
- Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal CarcinomaNot yet recruitingPhase 2Tang-Du HospitalNCT07752394Written as Finotonlimab
- Perioperative Finotonlimab Plus Chemotherapy in Untreated Stage II HNSCCNot yet recruitingPhase 2Yanjie Zhang, MDNCT07751276Written as Neoadjuvant Finotonlimab Plus Chemotherapy
- BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy ProgressionEnrolling by invitationPhase 2Sun Yat-sen UniversityNCT07618624Written as Finotonlimab
- Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCCRecruitingPhase 1Beijing Tongren HospitalNCT07040072Written as Stapokibart and Finotonlimab
- SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell CarcinomaStatus unknownPhase 3Sinocelltech Ltd.NCT04146402Written as SCT-I10A+chemo
- Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRCStatus unknownPhase 1Sinocelltech Ltd.NCT04229537Written as SCT-I10A
- Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or LymphomaStatus unknownPhase 1Sinocelltech Ltd.NCT03821363Written as SCT-I10A
Given beside what is tested · 3 — finotonlimab is usual care or a partner of the new treatment
- A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular CarcinomaRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT06986785Written as Finotonlimab
- SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular CarcinomaActive, not recruitingPhase 2/3Sinocelltech Ltd.NCT04560894Written as SCT-I10A
- SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaStatus unknownPhase 1Sinocelltech Ltd.NCT05552807Written as SCT-I10A
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered1
Codes
What other systems call finotonlimab · ClinicalTrials.gg INT014982
- UNII (FDA) 533Z4G2286FINOTONLIMABOne source FDA
- NCI Thesaurus C170758FinotonlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 533Z4G2286 | FINOTONLIMAB | One source FDA |
| NCI Thesaurus | C170758 | Finotonlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.